GlassScriptPhysician profile
Darren Wohl
NPI 1649289836
$7,617.74
in general payments reported to CMS, 2019-2025
32 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $758 · 2021: $1,139 · 2022: $1,598 · 2023: $1,266 · 2024: $969 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,954.20 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $910.74 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $862.26 | 2019-2023 | Exalt Model D |
| Gilead Sciences, INC. | $800.25 | 2019-2024 | |
| Janssen Biotech, INC. | $596.36 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $510.18 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $320.85 | 2019-2022 | |
| Ardelyx, INC. | $194.23 | 2024-2025 | Ibsrela |
| Celgene Corporation | $149.25 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $143.35 | 2020-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $133.06 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $132.44 | 2020-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $121.40 | 2021-2024 | Rebyota |
| Qol Medical, LLC | $96.59 | 2022-2023 | Sucraid |
| Redhill Biopharma INC. | $86.03 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $77.49 | 2020 | |
| Ironwood Pharmaceuticals, INC | $72.17 | 2021-2025 | |
| Pfizer INC. | $57.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $53.12 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $51.76 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $48.22 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $42.55 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $33.27 | 2025 | |
| Aimmune Therapeutics, INC. | $26.15 | 2024 | |
| Covidien LP | $23.06 | 2019 | |
| Intra-Sana Laboratories | $21.24 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.23 | 2025 | Terlivaz |
| Eagle Pharmaceuticals, INC. | $17.40 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.10 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $16.87 | 2020 | |
| Shire North American Group INC | $15.92 | 2019 | |
| Medtronic, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Wohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.